JNJ

230.29

+1.2%↑

ABBV

212.01

+2.9%↑

UNH

397.06

-0.95%↓

AZN

185.02

-0.17%↓

NVS

150.15

+0.52%↑

JNJ

230.29

+1.2%↑

ABBV

212.01

+2.9%↑

UNH

397.06

-0.95%↓

AZN

185.02

-0.17%↓

NVS

150.15

+0.52%↑

JNJ

230.29

+1.2%↑

ABBV

212.01

+2.9%↑

UNH

397.06

-0.95%↓

AZN

185.02

-0.17%↓

NVS

150.15

+0.52%↑

JNJ

230.29

+1.2%↑

ABBV

212.01

+2.9%↑

UNH

397.06

-0.95%↓

AZN

185.02

-0.17%↓

NVS

150.15

+0.52%↑

JNJ

230.29

+1.2%↑

ABBV

212.01

+2.9%↑

UNH

397.06

-0.95%↓

AZN

185.02

-0.17%↓

NVS

150.15

+0.52%↑

Home・Lista de Ações・Eli Lilly and Co.

Eli Lilly and Co.

Abrir

SetorSaúde

1,005.98 0.7

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

995

Máximo

1022.44

Indicadores-chave
By Trading Economics
Rendimento	758M 7.4B
Vendas	507M 20B
P/E Médio do Setor	34.327 51.415
EPS	8.55
Rendimento de Dividendos	0.66
Margem de lucro	37.355
Funcionários	50,000
EBITDA	971M 9.4B

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+24.33% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	0.66% 2.34%
Próximos Ganhos	5 de ago. de 2026
Próxima data de dividendos	10 de jun. de 2026
Próxima data de ex-dividendo	15 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	87B 862B
Abertura anterior	1005.28
Fecho anterior	1005.98

Sentimento de Notícias

By Acuity

41%

59%

132 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

N/A / 884.54 Suporte e Resistência

Eli Lilly and Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de abr. de 2026, 12:01 UTC

Ganhos

Grandes Movimentos do Mercado

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

7 de mai. de 2026, 09:30 UTC

Ganhos

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 de mai. de 2026, 12:36 UTC

Ganhos

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 de mai. de 2026, 10:12 UTC

Ganhos

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 de mai. de 2026, 09:58 UTC

Ganhos

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30 de abr. de 2026, 20:59 UTC

Ações em Alta

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30 de abr. de 2026, 20:12 UTC

Ganhos

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 de abr. de 2026, 16:43 UTC

Ganhos

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30 de abr. de 2026, 16:10 UTC

Conversa de Mercado

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30 de abr. de 2026, 15:13 UTC

Ganhos

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 de abr. de 2026, 14:58 UTC

Ganhos

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30 de abr. de 2026, 14:53 UTC

Ganhos

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30 de abr. de 2026, 14:50 UTC

Ganhos

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30 de abr. de 2026, 14:42 UTC

Ganhos

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30 de abr. de 2026, 14:39 UTC

Ganhos

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30 de abr. de 2026, 14:35 UTC

Ganhos

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30 de abr. de 2026, 14:24 UTC

Ganhos

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30 de abr. de 2026, 14:17 UTC

Ganhos

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30 de abr. de 2026, 13:56 UTC

Ganhos

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 de abr. de 2026, 13:37 UTC

Ações em Alta

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 de abr. de 2026, 12:32 UTC

Conversa de Mercado

Ganhos

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

30 de abr. de 2026, 12:29 UTC

Conversa de Mercado

Ganhos

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

30 de abr. de 2026, 12:23 UTC

Conversa de Mercado

Ganhos

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

30 de abr. de 2026, 12:10 UTC

Ganhos

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 de abr. de 2026, 12:08 UTC

Ganhos

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

30 de abr. de 2026, 12:04 UTC

Conversa de Mercado

Ganhos

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

30 de abr. de 2026, 11:39 UTC

Ações em Alta

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 de abr. de 2026, 11:08 UTC

Ganhos

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 de abr. de 2026, 10:50 UTC

Ganhos

Eli Lilly Raises 2026 Performance Margin View to 47%-48.5% From 46%-47.5% >LLY

30 de abr. de 2026, 10:49 UTC

Ganhos

Eli Lilly Had Seen 2026 Revenue $80B-$83B, Adjusted EPS $33.50-$35.00 >LLY

Comparação entre Pares

Variação de preço

Eli Lilly and Co. Previsão

Preço-alvo

By TipRanks

24.33% parte superior

Previsão para 12 meses

Média 1,262.85 USD 24.33%

Máximo 1,500 USD

Mínimo 850 USD

Com base em 22 analistas de Wall Street que oferecem metas de preço de 12 meses para Eli Lilly and Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

22 ratings

Comprar

Manter

Vender

Com base em 22 analistas que deram avaliações de ações para Eli Lilly and Co. - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

N/A / 884.54Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

132 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.